Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBERT trial of atezolizumab in unresectable alveolar soft part sarcoma
jRCT2031200041Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in alveolar soft part sarcoma (ASPS), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate. Started May 2020; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on jRCT2031200041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200041.